Biotech & TechBio startups in London

Jane Osbourne, Young Kwon

Founded 2019, identifies and develops naturally occurring protective antibodies from resilient individuals who avoid or survive disease, with a lead programme in ALS/neurodegeneration. Co-founder Jane Osbour...

Ken Mulvany

Founded 2013, one of the earliest AI-first drug-discovery companies, using its Benevolent Platform to mine biomedical data for novel targets. Listed on Euronext Amsterdam via SPAC in 2022 at ~€1.5B; cut staf...

Tania Boler, Alexander Asseily

Femtech/consumer-health hardware founded 2013 (as Chiaro), maker of the silent wearable Elvie Pump breast pump and Elvie Trainer pelvic-floor device. Raised a £70.7M Series C in 2021 (a landmark femtech roun...

Michelle Teng

TechBio founded 2020 using its EMLy generative-AI immune-intelligence platform (LLM-style models on the world's largest ML immune dataset) to design T-cell receptor (TCR) therapeutics. Positioned as one of t...

Dmitry Gurski, Yuri Gurski

Femtech founded 2015; the world's most-downloaded period, cycle and pregnancy tracking app with 70M+ monthly users. In 2024 raised a $200M Series C led by General Atlantic at a $1B+ valuation, making it Euro...

Demis Hassabis

Founded 2021 as an Alphabet company spun out of Google DeepMind, applying AlphaFold-derived AI to rational drug design. In 2024 struck research collaborations with Eli Lilly and Novartis; in April 2025 raise...

London AI-drug-discovery company spun out of Google DeepMind (led by Demis Hassabis), applying AlphaFold-derived models to design new medicines with pharma partners. Raised its first external round of $600m ...

James Field

Founded 2012, uses its EVA closed-loop platform (ML + robotic automation + synthetic biology) to design next-generation therapeutic antibodies for solid tumours. Raised a £35M Series B in May 2024 led by M V...

Meri Beckwith, Michael Young

Founded 2021, the self-styled 'anti-CRO' offering a tech-enabled platform to run clinical trials faster and cheaper end-to-end. Raised a $55M Series B in 2025 led by Balderton, bringing total funding to ~$81...

Mridula Pore, Evan Harris, Max Landry

Founded 2018 at 13 Southampton Place; a B2B employee-benefit platform giving staff expert support in menopause, fertility, men's health and early parenthood. Raised a £37.1M (~$45M) Series B in January 2023 ...

Kamil Tamiola

Pre-clinical 'protein intelligence' TechBio founded 2017/2018 combining AI and experimental biophysics to drug intrinsically disordered proteins that AlphaFold cannot model. Backed by F-Prime and others; ~$4...

Syncona-backed team

AAV gene-therapy company (Syncona portfolio) targeting kidney disease. In 2024 raised £80M (~$105M) in a Series B to take its lead candidate PS-002, an AAV gene therapy for IgA nephropathy (IgAN), into Phase...

foundational team (UCL/King's spinout)

Cell-therapy biotech founded 2019 engineering regulatory T-cell (Treg) therapies for transplant rejection and autoimmune disease. Raised a ~£48.9M round in 2024 and secured a licensing deal with AstraZeneca ...

Lindsay Edwards, David Roblin, Charles Roberts

TechBio founded 2019 combining graph machine learning with functional genomics ('Lab-in-the-Loop') to find disease drivers, initially in osteoporosis and fibrosis. In late 2024 signed a strategic collaborati...